Viking Therapeutics Inc. (VKTX)
Shareholder Rights Advocates at Levi & Korsinsky Investigate Viking Therapeutics, Inc. (VKTX) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.
Levi & Korsinsky Reminds Shareholders of an Investigation into Viking Therapeutics, Inc. (VKTX) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.
Is Viking Therapeutics a Buy on the Dip?
Viking stock has slipped more than 20% from its peak.
Lost Money on Viking Therapeutics, Inc. (VKTX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.
4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move
All signs are pointing toward its continued success.
Got $5,000? Viking Therapeutics Stock Just Got a Big New Green Flag
The company's latest presentation supports the idea that its lead program will make billions.
ATTENTION Viking Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
NEW YORK CITY, NY / ACCESSWIRE / November 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Is Viking Therepautics a Buy Now?
The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.
Why Viking Therapeutics Stock Plummeted After Soaring Today
Are we ready for the Great Obesity Drug Gold Rush of the 2020s?
Viking Therapeutics soars then drops on obesity data
Jared Holz, Mizuho, joins 'Fast Money' to talk Viking Therapeutics and the biotech sector.
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Viking Therapeutics' oral VK2735 reported strong weight loss and good safety and tolerability in the phase 1 trial, with the 100mg dose achieving 8.2% absolute weight loss in four weeks. These results put Viking at the front of the oral obesity field, but with a major caveat of rapid treatment landscape evolution. The sell the news reaction is understandable given high investor excitement ahead of the data update, and the fact there are no meaningful catalysts until at least Q4 2025.
